FR2965178B1 - Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer - Google Patents

Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Info

Publication number
FR2965178B1
FR2965178B1 FR1003859A FR1003859A FR2965178B1 FR 2965178 B1 FR2965178 B1 FR 2965178B1 FR 1003859 A FR1003859 A FR 1003859A FR 1003859 A FR1003859 A FR 1003859A FR 2965178 B1 FR2965178 B1 FR 2965178B1
Authority
FR
France
Prior art keywords
alzheimer
disease
treatment
pharmaceutical composition
composition used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1003859A
Other languages
English (en)
Other versions
FR2965178A1 (fr
Inventor
Sebastien Lasnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1003859A priority Critical patent/FR2965178B1/fr
Priority to PCT/FR2011/000528 priority patent/WO2012042128A1/fr
Publication of FR2965178A1 publication Critical patent/FR2965178A1/fr
Application granted granted Critical
Publication of FR2965178B1 publication Critical patent/FR2965178B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR1003859A 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer Active FR2965178B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1003859A FR2965178B1 (fr) 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
PCT/FR2011/000528 WO2012042128A1 (fr) 2010-09-29 2011-09-27 Composition pharmaceutique comprenant de la memantine et de la vitamine d pour le traitement de la maladie d 1 alzheimer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1003859A FR2965178B1 (fr) 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
FR2965178A1 FR2965178A1 (fr) 2012-03-30
FR2965178B1 true FR2965178B1 (fr) 2012-10-05

Family

ID=43304969

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1003859A Active FR2965178B1 (fr) 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Country Status (2)

Country Link
FR (1) FR2965178B1 (fr)
WO (1) WO2012042128A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss

Also Published As

Publication number Publication date
FR2965178A1 (fr) 2012-03-30
WO2012042128A1 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
JP2015501783A5 (fr)
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EP2151435A4 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
HK1150390A1 (en) A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
SG10201704712QA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EP2568811A4 (fr) Traitement du tcl et de la maladie d'alzheimer
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
FR2934267B1 (fr) Derives aminophosphiniques utiles dans le traitement de la douleur
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
EA201690659A1 (ru) Композиции аморфного магнийзамещенного фосфата кальция и их применение
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
FR2993564B1 (fr) Derives d'imidazopyridine utiles dans le traitement du diabete
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
FR2963237B1 (fr) Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain
FR2965178B1 (fr) Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14